Active, Not Recruiting Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy NCT05000710 Conditions Metastatic or Locally Advanced NSCLC, Neoplasm Metastasis, Neoplasms, +3 more Locations Sheba Medical Centre — Ramat Gan, Israel View Trial Details
